Are EVMN insiders buying or selling?

In the last 90 days, Evommune (EVMN) had 0 insider transactions. Track every executive trade, dollar amount, and date.

Which hedge funds own EVMN?

See every hedge fund and asset manager holding Evommune (EVMN).

How much of EVMN trades in dark pools?

0.696M EVMN shares ($14M notional) traded off-exchange last week — block trades typical of institutional flow.

Evommune (EVMN) — Hedge Funds Added +$207M Q-o-Q

$11.25

-0.22 (-1.92%)

Weekly Expected Move ±22.6%

$6 $9 $11 $14 $17

NYSE · Healthcare · Biotechnology · Alpha Radar Strong Sell · Power 28 · $159.3M mcap · 14M float · 5.60% daily turnover · Short 35% of daily vol

Smart Money Score

Moderate 50

Insider—

Congress—

ETF Holdings—

Key Statistics

Market Cap$159.3M

52W Range10.47-33.2

Volume699,420

Avg Volume773,583

Beta0.86

Dividend—

Analyst Ratings

2 Buy 2 Hold 0 Sell

Consensus Buy

Company Info

CEOLuis C. Pena

Employees48

SectorHealthcare

IndustryBiotechnology

IPO Date2025-11-06

Websiteevommune.com

1841 Page Mill Road
Palo Alto, CA 94304
US

(925) 247-4487

About Evommune, Inc.

Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.

Latest News